Table 1: Patient characteristics.

AgeGenderNY-ESO-1 immuno-histochemistryHLA-A2HLA-DP4ECOG performance statusTime to progression
(months)
Overall survival
(months)

43F3+++11.93.8
26F4+++10.919.7
56M3+++01.913.7
32F3++12.13.2
57F3+20.50.8
23M2+++11.813.7